CARL ICAHN owns 1.4% of Illumina, a genomics giant with a market value of $34bn. Mr Icahn’s modest stake belies his ambition. As the elder statesman of activist investing, the 87-year-old aims...
One of the joys of writing about business is that rare moment when you realise conventions are shifting in front of you. It brings a shiver down the spine. Vaingloriously, you start...
On May 22nd the EU whacked Meta with a €1.2bn ($1.3bn) fine for transferring users’ data to America, in breach of European privacy rules (which turn five this week). The social-media giant...
“TODAY WE SEE the birth of a new species,” declared Julio Friedmann, gazing across the bleak landscape. Along with several hundred grandees, the renowned energy technologist had travelled to a remote corner...
Living in California, as Schumpeter does, you would think licence plates called it the Red Tape State, not the golden one. Last August it led the world in announcing a ban on...
“The Goal” is a notable business book for two reasons. The first is its unusual genre. First published in 1984, it is a management tome dressed up in the clothes of a...
Given the political weather, Western makers of wind turbines should be flying high. America’s Inflation Reduction Act is stuffed with goodies for all sorts of renewable energy. In late April European leaders...
It had all the hallmarks of a coming-out party—or, more accurately, a coming-out-again one. After being uncharacteristically absent from public view for a few years, Mukesh Ambani re-emerged at the end of...
